2024 Albania Immunoassay Analyzers and Reagents--2023 Supplier Shares and Competitive Analysis, 2023-2028 Volume and Sales Segment Forecasts for 100 Abused Drugs, Cancer Diagnostic, Endocrine Function, Immunoproteins, TDMs, and Special Chemistry Tests--Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

February 2024 | | ID: 2E9401214763EN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunoassay markets during the next five years.The report is available by section, and can be customized to specific information needs and budget. The report provides specimen, test volume and Sales Segment forecasts; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

Rationale

The clinical chemistry and immunoassay markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Individual Tests Analyzed in the Report

Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin (Direct), Bilirubin (Total), BNP, BUN (Blood Urea Nitrogen), Calcium, Carbon Dioxide/Bicarbonate, Cardio CRP, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Cystatin C, Ferritin, Fructosamine, GGT, Glucose, HDL Cholesterol, Homocysteine, hs-CRP, Insulin, Iron, Iron (Total Binding Capacity), Iron (Unsaturated Binding Capacity), LDH, LDL Cholesterol, LDL Cholesterol Direct, Lipase, Lipoprotein a, Magnesium, Microalbumin, NT-proBNP, Phosphorus, Potassium, Sodium, ST2, Total Protein, Triglycerides, Troponin, Uric Acid

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Free, T3 Uptake, T4, T4 Free, TBG, Testosterone, Thyroglobulin Ab, TPO Ab, TSH

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B-12

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM, Immunofixation, Prealbumin, Protein Electrophoresis

Drugs of Abuse

Amphetamines, Antidepressants, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine, LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP), Propoxyphene, Tricyclic Antidepressants

Current and Emerging Products

• Analysis of current and emerging clinical chemistry and immunoassay tests.
• Review of current instrumentation technologies, and feature comparison of high-, medium-, and low-volume/POC analyzers.

Technology Assessment

• Assessment of current and emerging technologies, and their potential market applications.
• Comprehensive lists of companies developing or marketing new technologies and products by test.

Strategic Recommendations

• New product development opportunities with significant market appeal.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Competitive Assessments

• Strategic assessments of major suppliers and emerging market entrants, including their sales segment, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

Contents

I. Introduction
II. Market Overview

1. BUSINESS ENVIRONMENT


2. MARKET STRUCTURE


3. MARKET SIZE AND GROWTH

III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Market and Technology Overview
A. Major Routine Chemistry Tests

1. ALBUMIN


2. ALKALINE PHOSPHATASE


3. ALT/SGPT


4. AMMONIA


5. AMYLASE


6. AST/SGOT


7. BILIRUBIN, TOTAL


8. BLOOD GASES


9. BLOOD UREA NITROGEN (BUN)


10. CALCIUM


11. CARDIO CRP


12. CHOLESTEROL


13. CHOLINESTERASE


14. CRP


15. CREATININE


16. ELECTROLYTES

a. Carbon Dioxide/Bicarbonate
b. Chloride
c. Potassium
d. Sodium

17. FERRITIN


18. FRUCTOSAMINE


19. GAMMA-GLUTAMYL TRANSPEPTIDASE (GGT)


20. GLUCOSE


21. HIGH DENSITY LIPOPROTEIN (HDL)


22. HOMOCYSTEINE


23. IRON


24. LACTATE DEHYDROGENASE (LDH)


25. MAGNESIUM


26. PHOSPHORUS


27. PROTEIN


28. TRIGLYCERIDES


29. URIC ACID


30. TROPONIN

B. Therapeutic Drug Monitoring (TDM)

1. OVERVIEW


2. CARBAMAZEPINE


3. CYCLOSPORIN


4. DIGOXIN


5. EVEROLIMUS


6. GENTAMICIN


7. LAMOTRIGINE/LAMICTAL


8. LEVETIRACETAM


9. LIDOCAINE


10. LITHIUM


11. NAPA/PROCAINAMIDE


12. PHENYTOIN


13. QUINIDINE